The latest announcement is out from Trendlines Group ( (SG:42T) ).
The Trendlines Group Ltd. addressed queries from the Securities Investors Association (Singapore) regarding its FY2024 Annual Report, highlighting key capital transactions for its portfolio companies, including Vessi Medical and Vensica Medical. Despite securing approximately US$42 million in external capital, the group reported a net loss of US$(10.2) million, attributed to write-downs and write-offs of several portfolio companies. The fair value of these companies declined due to lower funding rounds and dimmer prospects, with 12 companies written off over two years. The company is assessing these outcomes to refine future investment strategies.
More about Trendlines Group
The Trendlines Group Ltd., incorporated in Israel, operates in the investment industry, focusing on nurturing and developing portfolio companies primarily in the medical and agricultural technology sectors. The company is involved in securing external capital for its portfolio companies to advance their commercial and clinical initiatives.
YTD Price Performance: -38.00%
Average Trading Volume: 351,139
Technical Sentiment Signal: Buy
Current Market Cap: S$34.95M
See more data about 42T stock on TipRanks’ Stock Analysis page.